| scholarly article | Q13442814 |
| P356 | DOI | 10.1176/AJP.2006.163.4.600 |
| 10.1176/APPI.AJP.163.4.600 | ||
| P698 | PubMed publication ID | 16585434 |
| P5875 | ResearchGate publication ID | 7195457 |
| P50 | author | Robert A. Rosenheck | Q21094933 |
| Joanne B Severe | Q109419684 | ||
| Jeffrey Lieberman | Q6176130 | ||
| P2093 | author name string | Richard S E Keefe | |
| Herbert Y Meltzer | |||
| Marvin S Swartz | |||
| Diana O Perkins | |||
| John K Hsiao | |||
| Joseph P McEvoy | |||
| T Scott Stroup | |||
| Sonia M Davis | |||
| Clarence E Davis | |||
| CATIE Investigators | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| patient | Q181600 | ||
| risperidone | Q412443 | ||
| chronic schizophrenia | Q18967121 | ||
| P1104 | number of pages | 11 | |
| P304 | page(s) | 600 | |
| 600-610 | |||
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment | |
| Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment | |||
| P478 | volume | 163 |
| Q34018491 | 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). |
| Q36054749 | A Case of Clozapine-Induced Myocarditis in a Young Patient with Bipolar Disorder |
| Q97430870 | A clozapine-induced hypersensitivity reaction |
| Q90353605 | A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future |
| Q36843480 | A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice |
| Q90427479 | A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter |
| Q50750295 | A framework to avoid irrational polypharmacy in psychiatry. |
| Q38496254 | A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia. |
| Q28487183 | A genome-wide RNAi screen in Caenorhabditis elegans identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target |
| Q34287887 | A multiple imputation strategy for sequential multiple assignment randomized trials |
| Q37998840 | A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. |
| Q36573892 | A review of atypical antipsychotic drugs versus conventional medication in schizophrenia |
| Q24678461 | A roadmap to key pharmacologic principles in using antipsychotics |
| Q38156174 | A therapeutic interaction between cimetidine and clozapine: case study and review of the literature |
| Q30485065 | A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy |
| Q36905070 | Adding or switching antipsychotic medications in treatment-refractory schizophrenia |
| Q37405519 | Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia |
| Q43260114 | Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission |
| Q34129991 | Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine |
| Q37409661 | Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children |
| Q39855010 | Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia |
| Q51464719 | Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q30491026 | An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients |
| Q36236693 | Analysis of differential gene expression mediated by clozapine in human postmortem brains |
| Q36449077 | Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PET |
| Q37137001 | Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials |
| Q33160283 | Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management |
| Q53169797 | Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. |
| Q34269517 | Antipsychotic polypharmacy in a regional health service: a population-based study. |
| Q84299593 | Antipsychotic treatment of first-episode or early-onset schizophrenia |
| Q37188995 | Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal |
| Q37725147 | Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making |
| Q30370326 | Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. |
| Q56791146 | Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study |
| Q38070179 | Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults |
| Q50888723 | Assessment of medical devices: how to conduct comparative technology evaluations of product performance. |
| Q104073748 | Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia |
| Q34965470 | Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results |
| Q53091132 | Augmentation of clozapine with a second antipsychotic - a meta-analysis. |
| Q38256894 | Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine |
| Q61801836 | Barriers to using clozapine in treatment-resistant schizophrenia: systematic review |
| Q34144373 | Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence |
| Q48909820 | Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. |
| Q37216921 | Better pharmacotherapy for schizophrenia: what does the future hold? |
| Q42648540 | Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia |
| Q38966498 | Blood Pressure and Heart Rate Changes During Clozapine Treatment |
| Q43262808 | Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea |
| Q38762872 | Brain-imaging studies of treatment-resistant schizophrenia: a systematic review |
| Q35359733 | Burning pain secondary to clozapine use: a case report |
| Q37091444 | Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone |
| Q36714070 | Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study |
| Q35802879 | Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish. |
| Q54959236 | Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. |
| Q44228933 | Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia |
| Q37626797 | Changes in physician antipsychotic prescribing preferences, 2002-2007. |
| Q37212118 | Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial |
| Q90264428 | Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View |
| Q37643030 | Clinical Practice Guidelines for Management of Schizophrenia |
| Q38799868 | Clinical factors related to schizophrenia relapse |
| Q34048575 | Clinical features of schizophrenia with enhanced carbonyl stress. |
| Q44830864 | Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission i |
| Q38706468 | Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis |
| Q38885071 | Clozapine Treatment and Cannabis Use in Adolescents with Psychotic Disorders - A Retrospective Cohort Chart Review |
| Q39763748 | Clozapine administration in clinical practice: once-daily versus divided dosing |
| Q39480375 | Clozapine and visuospatial processing in treatment-resistant schizophrenia |
| Q39400094 | Clozapine as a Model for Antipsychotic Development |
| Q58738328 | Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis |
| Q24186084 | Clozapine augmentation for treatment-resistant schizoaffective disorder |
| Q38026886 | Clozapine for the treatment of schizophrenia |
| Q61795776 | Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial |
| Q48881589 | Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. |
| Q83808358 | Clozapine is gold standard, but questions remain |
| Q41965901 | Clozapine is underutilized |
| Q35906545 | Clozapine prescribing in the UK: views and experience of consultant psychiatrists |
| Q40815632 | Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records |
| Q37076129 | Clozapine underutilization and discontinuation in African Americans due to leucopenia |
| Q41734144 | Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia |
| Q57041761 | Clozapine use in children and adolescents |
| Q50618508 | Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample. |
| Q31115350 | Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. |
| Q34112064 | Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study |
| Q24236422 | Clozapine versus other atypical antipsychotics for schizophrenia |
| Q24244994 | Clozapine versus other atypical antipsychotics for schizophrenia |
| Q35113758 | Clozapine-Induced Late Agranulocytosis and Severe Neutropenia Complicated with Streptococcus pneumonia, Venous Thromboembolism, and Allergic Vasculitis in Treatment-Resistant Female Psychosis |
| Q46092553 | Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. |
| Q36908979 | Clozapine-induced hypersalivation: a review of treatment strategies |
| Q46983509 | Clozapine-induced leukopenia successfully treated with lithium |
| Q41111202 | Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain |
| Q37097619 | Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives |
| Q28274106 | Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review |
| Q35948871 | Clozapine-induced stuttering: an estimate of prevalence in the west of Ireland |
| Q34021447 | Clozapine: Current perspective |
| Q21260307 | Clozapine: a review of clinical practice guidelines and prescribing trends |
| Q43186526 | Clozapine: agonistic and antagonistic salivary secretory actions |
| Q50631593 | Clozapine: is now the time for more clinicians to adopt this orphan? |
| Q34603527 | Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder |
| Q93560510 | Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review |
| Q27015872 | Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment |
| Q42052463 | Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors |
| Q37337682 | Comorbid psychiatric and substance abuse disorders: recent treatment research |
| Q38016230 | Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? |
| Q30882594 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data |
| Q33568876 | Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study |
| Q64082319 | Comparison of clozapine monitoring and adverse event management in a psychiatrist-only and a clinical pharmacist-psychiatrist collaborative clinic |
| Q37339072 | Comparisons between psychotropic drugs: must the risk of side effects dictate our practices? |
| Q37163467 | Compelling or irrelevant? Using number needed to treat can help decide |
| Q36909124 | Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. |
| Q34413977 | Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial |
| Q42938340 | Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia |
| Q43475436 | Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication |
| Q35236864 | Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
| Q33521559 | Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data |
| Q37185914 | Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States |
| Q37011447 | Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability |
| Q24650594 | Current perspectives in the treatment of resistant schizophrenia |
| Q42946206 | Current status of clozapine in the United States |
| Q48650684 | Development of an outpatient pharmacist-managed clozapine clinic. |
| Q48590341 | Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. |
| Q102209001 | Differentiating Tardive Dyskinesia: A Video-Based Review of Antipsychotic-Induced Movement Disorders in Clinical Practice |
| Q39302471 | Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. |
| Q33953271 | Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008 |
| Q37214661 | Do effectiveness ("real world") studies on antipsychotics tell us the real truth? |
| Q43180348 | Does clozapine promote employability and reduce offending among mentally disordered offenders? |
| Q48283069 | Does early antipsychotic response predict long-term treatment outcome? |
| Q47618934 | Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice |
| Q37405204 | Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response |
| Q38079668 | Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design |
| Q36515996 | EQUIP: implementing chronic care principles and applying formative evaluation methods to improve care for schizophrenia: QUERI Series. |
| Q37940737 | Economic approaches to improving access to evidence-based and recovery-oriented services for people with severe mental illness |
| Q33157593 | Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects |
| Q50625457 | Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. |
| Q37102823 | Effectiveness as an outcome measure for treatment trials in psychiatry |
| Q46553469 | Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidon |
| Q51811285 | Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. |
| Q30387361 | Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test |
| Q37480943 | Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia |
| Q47101612 | Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia |
| Q46533468 | Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial |
| Q38068636 | Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses |
| Q46774609 | Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. |
| Q38040133 | Epigenetics of psychoactive drugs |
| Q92305969 | Establishing an effective dose for chronic intracerebroventricular administration of clozapine in mice |
| Q36330858 | Estimating the optimal dynamic antipsychotic treatment regime: Evidence from the sequential multiple assignment randomized CATIE Schizophrenia Study |
| Q42008097 | Ethical considerations when treating patients with schizophrenia. |
| Q47907288 | Evaluating complex medical treatment options: a case report |
| Q38284625 | Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder |
| Q48933903 | Evidence-based pharmacotherapy of schizophrenia. |
| Q47788587 | Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder |
| Q47875178 | Exploring personal recovery in mental illness through an Arabic sociocultural lens |
| Q37860249 | Factors affecting interindividual differences in clozapine response: a review and case report |
| Q37300007 | Factors associated with response to clozapine in schizophrenia: a review |
| Q37476441 | Fibroblast growth factors in schizophrenia |
| Q34021750 | Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine |
| Q50556051 | First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia. |
| Q43866267 | Gender differences in first episode psychosis |
| Q36756159 | Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia |
| Q64990277 | Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. |
| Q38444551 | Glutamatergic agents for schizophrenia: current evidence and perspectives |
| Q42544021 | Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? |
| Q37224949 | Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology |
| Q48253986 | Glycopyrrolate for treatment of clozapine-induced sialorrhea in adults |
| Q55252445 | Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. |
| Q55241644 | Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. |
| Q51907877 | How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. |
| Q64999981 | Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. |
| Q40012236 | Identifying patient-relevant endpoints among individuals with schizophrenia: an application of patient-centered health technology assessment |
| Q38632506 | Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia |
| Q37315451 | Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia |
| Q37085531 | Implications of CATIE for mental health services researchers. |
| Q36535311 | Incorporating clinical guidelines through clinician decision-making |
| Q24628874 | Increasing off-label use of antipsychotic medications in the United States, 1995-2008 |
| Q36946132 | Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics |
| Q43497929 | Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms |
| Q35057288 | Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature |
| Q43201052 | Ingenuity pathway analysis of clozapine-induced obesity. |
| Q40224374 | Interpreting and Applying the CATIE Results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. |
| Q53006399 | Interpreting the efficacy findings in the CATIE study: what clinicians should know. |
| Q44017981 | Involuntary treatment of schizophrenia patients 2004-2010 in Denmark |
| Q33937346 | Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series |
| Q35007214 | Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia |
| Q37178608 | Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. |
| Q91790829 | Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons |
| Q30421478 | Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood |
| Q37987985 | Lurasidone for schizophrenia: what's different? |
| Q35005165 | Lurasidone: a new drug in development for schizophrenia |
| Q33612521 | Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II |
| Q35082389 | Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia |
| Q36503217 | Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants |
| Q50664318 | Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. |
| Q41449760 | Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example |
| Q37441628 | Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia |
| Q34039590 | Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study |
| Q36133400 | N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms |
| Q84005904 | Neuropsychiatric disorders: The choice of antipsychotics in schizophrenia |
| Q43024782 | Of rats and schizophrenia. |
| Q37546091 | Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? |
| Q24236545 | Olanzapine versus other atypical antipsychotics for schizophrenia |
| Q51792951 | Optimizing clozapine through clinical decision making. |
| Q37532575 | Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making |
| Q44263856 | Outcomes for schizophrenia patients with clozapine treatment: how good does it get? |
| Q37174029 | Overview of the findings from the European SOHO study |
| Q34449894 | Paliperidone: the evidence of its therapeutic value in schizophrenia |
| Q34726953 | Past and present progress in the pharmacologic treatment of schizophrenia |
| Q37425367 | Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. |
| Q33627482 | Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample. |
| Q43043460 | Patterns of clozapine prescribing in a mental health service in New Zealand |
| Q24187359 | Perphenazine for schizophrenia |
| Q35237132 | Personalized medicine in psychiatry: ethical challenges and opportunities. |
| Q37956206 | Pharmacogenetics in psychiatry: translating research into clinical practice. |
| Q36539833 | Pharmacogenetics of antipsychotics: recent progress and methodological issues |
| Q24604457 | Pharmacologic treatment of schizophrenia |
| Q24598636 | Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review |
| Q24187704 | Pharmacological interventions for clozapine-induced sinus tachycardia |
| Q26471506 | Pharmacological interventions for clozapine-induced sinus tachycardia |
| Q37165503 | Pharmacological management of atypical antipsychotic-induced weight gain. |
| Q36715888 | Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? |
| Q38051438 | Pharmacological treatment of schizophrenia |
| Q34274859 | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents |
| Q37831352 | Pharmacotherapy for treatment-refractory schizophrenia |
| Q34879109 | Pharmacotherapy for treatment-resistant schizophrenia. |
| Q38203063 | Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective |
| Q47319403 | Physical Health and Drug Safety in Individuals with Schizophrenia. |
| Q28302151 | Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders |
| Q34798909 | Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy |
| Q57317032 | Polypharmazie bei schizophrenen Psychosen |
| Q33858281 | Potential role of patients' CYP3A-status in clozapine pharmacokinetics. |
| Q33709704 | Predictors of switching antipsychotic medications in the treatment of schizophrenia |
| Q37231036 | Prescribing and monitoring clozapine in Christchurch |
| Q37310164 | Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment |
| Q37279671 | Professionals' perception on the management of patients with dual disorders |
| Q37661476 | Progress in defining optimal treatment outcome in schizophrenia |
| Q37999566 | Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis |
| Q38016975 | Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? |
| Q64082308 | Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management |
| Q46150844 | Psychiatrists' attitude towards and knowledge of clozapine treatment |
| Q37104411 | Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey |
| Q47730385 | Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress |
| Q57602668 | QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment |
| Q92460908 | Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China |
| Q34965927 | Quetiapine in the treatment of schizophrenia and related disorders |
| Q24202427 | Quetiapine versus other atypical antipsychotics for schizophrenia |
| Q24240989 | Quetiapine versus other atypical antipsychotics for schizophrenia |
| Q34585989 | Quetiapine: dose-response relationship in schizophrenia |
| Q36184331 | Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context. |
| Q37075598 | Randomized controlled trials for schizophrenia: study designs targeted to distinct goals |
| Q26863435 | Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives |
| Q34331847 | Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder |
| Q89257437 | Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review |
| Q41833495 | Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. |
| Q33942094 | Recent advances in understanding schizophrenia |
| Q36946135 | Reducing variation in the pharmacologic treatment of schizophrenia: defining acceptable standards of treatment |
| Q46834629 | Refractory schizophrenia |
| Q37251173 | Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures |
| Q36693011 | Restarting clozapine after neutropenia: evaluating the possibilities and practicalities |
| Q30487308 | Results of phase 3 of the CATIE schizophrenia trial |
| Q30383064 | Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. |
| Q36715883 | Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia |
| Q37049609 | Risks and Benefits of Rapid Clozapine Titration |
| Q47681492 | Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes |
| Q24234950 | Risperidone versus other atypical antipsychotics for schizophrenia |
| Q50903681 | Role of MKP-1 (DUSP1) in clozapine-induced effects on the ERK1/2 signaling pathway in the rat frontal cortex. |
| Q36026776 | Role of aripiprazole in treatment-resistant schizophrenia |
| Q34680925 | Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. |
| Q50779681 | Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. |
| Q37862242 | Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment |
| Q34973585 | Schizophrenia proteomics: biomarkers on the path to laboratory medicine? |
| Q22251476 | Schizophrenia, “Just the Facts”: What we know in 2008 |
| Q37428125 | Second-generation antipsychotics for schizophrenia: can we resolve the conflict? |
| Q59784175 | Second-generation antipsychotics: a therapeutic downturn? |
| Q28303010 | Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis |
| Q48617350 | Selected cytokine profiles during remission in bipolar patients. |
| Q46376152 | Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study |
| Q49852152 | Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis. |
| Q92972061 | Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life? |
| Q24621711 | Substance abuse and schizophrenia: pharmacotherapeutic intervention |
| Q38948365 | Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections |
| Q58760344 | Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis |
| Q33566124 | The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q45931497 | The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. |
| Q49481418 | The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. |
| Q48273932 | The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions |
| Q33950877 | The appropriateness of routine medication treatment for schizophrenia. |
| Q38662839 | The association between season of birth, age at onset, and clozapine use in schizophrenia |
| Q43234864 | The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series |
| Q49083919 | The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex. |
| Q37018470 | The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries |
| Q30487850 | The evolution of drug development in schizophrenia: past issues and future opportunities |
| Q26821785 | The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function |
| Q91359345 | The impact of switching to clozapine on psychiatric hospital admissions: a mirror-image study |
| Q46167864 | The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study |
| Q37344831 | The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18. |
| Q37076060 | The neuropharmacology of psychosis |
| Q35370032 | The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics |
| Q36898681 | The pipeline and future of drug development in schizophrenia. |
| Q42682469 | The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks |
| Q38268878 | Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia |
| Q46742317 | Three cases of schizophrenia for which olanzapine was effective after early acute phase |
| Q91583150 | Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study |
| Q42204241 | Treatment of Hypochondriasis in Two Schizophrenia Patients Using Clozapine |
| Q35864793 | Treatment of early onset schizophrenia: recent trends, challenges and future considerations |
| Q37162884 | Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. |
| Q33488323 | Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients |
| Q57166998 | Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives |
| Q35256929 | Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials |
| Q37852818 | Treatment strategies for dosing the second generation antipsychotics. |
| Q38646571 | Trends in the prescription of clozapine in a psychiatric hospital: a 5-year observational study |
| Q34587166 | Unanswered questions in schizophrenia clinical trials |
| Q89027481 | Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy |
| Q50732813 | Use of clozapine in a state child and adolescent psychiatric hospital. |
| Q38659786 | Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. |
| Q34591378 | What CATIE found: results from the schizophrenia trial |
| Q35868866 | When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature |
| Q36768035 | When should clozapine be initiated in schizophrenia?: Some arguments for and against earlier use of clozapine |
| Q37801988 | Where to position clozapine: re-examining the evidence |
| Q34640811 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance |
| Q79398825 | Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder |
| Q53801328 | [Negative symptoms in schizophrenia: new pharmacological approaches]. |
Search more.